Yong Xu

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 23

Top Topics

Acute Myeloid Leukemia

Structural Basis

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Journal of medicinal chemistry

Chemistry & biodiversity

Scientific reports

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Wenhua Jiang, Qiangqiang Hou, Hongrui Xu, Kexin Yang, Xiaohui Wang, Kuojun Zhang, Yi Zeng, Wenqiang Li, Bingrui Wang, Guangmei Luo, Xiaofan Zhao, Hui Shen, Yong Xu, Xiaoxing Wu
Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia. Journal of medicinal chemistry 67 (2) (2024)
Run Zhu, Junhua Li, Ruibo Dong, Qingqing Hu, Zhiming Chen, Xiaoshan Chen, Zhixin Zhong, Qiuping Xiang, Cen Huang, Bin Lin, Xishan Wu, Yan Zhang, Linxiang Zhao, Yong Xu
Optimization of the synthesis of BET BD2 selective inhibitor XY153. Chemistry & biodiversity (2024)
Tianbang Wu, Jiankang Hu, Xiaofan Zhao, Cheng Zhang, Ruibo Dong, Qingqing Hu, Hongrui Xu, Hui Shen, Xiaohan Zhang, Yan Zhang, Bin Lin, Xishan Wu, Qiuping Xiang, Yong Xu
Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia. Journal of medicinal chemistry 67 (11) (2024)
Run Zhu, Junhua Li, Ruibo Dong, Qingqing Hu, Zhiming Chen, Xiaoshan Chen, Zhixin Zhong, Qiuping Xiang, Cen Huang, Bin Lin, Xishan Wu, Yan Zhang, Linxiang Zhao, Yong Xu
Optimization of the synthesis of BET BD2 selective inhibitor XY153. Chemistry & biodiversity 21 (2) (2024)
Jiankang Hu, Hongrui Xu, Tianbang Wu, Cheng Zhang, Hui Shen, Ruibo Dong, Qingqing Hu, Qiuping Xiang, Shuang Chai, Guolong Luo, Xiaoshan Chen, Yumin Huang, Xiaofan Zhao, Chao Peng, Xishan Wu, Bin Lin, Yan Zhang, Yong Xu
Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity. Journal of medicinal chemistry 67 (9) (2024)
Jiankang Hu, Yong Xu
CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond. Journal of medicinal chemistry 67 (7) (2024)
Jiankang Hu, Yong Xu
CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond. Journal of medicinal chemistry 67 (7) (2024)
Jiankang Hu, Hongrui Xu, Tianbang Wu, Cheng Zhang, Hui Shen, Ruibo Dong, Qingqing Hu, Qiuping Xiang, Shuang Chai, Guolong Luo, Xiaoshan Chen, Yumin Huang, Xiaofan Zhao, Chao Peng, Xishan Wu, Bin Lin, Yan Zhang, Yong Xu
Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity. Journal of medicinal chemistry (2024)
Jiankang Hu, Yong Xu
CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond. Journal of medicinal chemistry (2024)
Run Zhu, Junhua Li, Ruibo Dong, Qingqing Hu, Zhiming Chen, Xiaoshan Chen, Zhixin Zhong, Qiuping Xiang, Cen Huang, Bin Lin, Xishan Wu, Yan Zhang, Linxiang Zhao, Yong Xu
Optimization of the synthesis of BET BD2 selective inhibitor XY153. Chemistry & biodiversity 21 (2) (2024)
Tianbang Wu, Jiankang Hu, Xiaofan Zhao, Cheng Zhang, Ruibo Dong, Qingqing Hu, Hongrui Xu, Hui Shen, Xiaohan Zhang, Yan Zhang, Bin Lin, Xishan Wu, Qiuping Xiang, Yong Xu
Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia. Journal of medicinal chemistry (2024)
Wenhua Jiang, Qiangqiang Hou, Hongrui Xu, Kexin Yang, Xiaohui Wang, Kuojun Zhang, Yi Zeng, Wenqiang Li, Bingrui Wang, Guangmei Luo, Xiaofan Zhao, Hui Shen, Yong Xu, Xiaoxing Wu
Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia. Journal of medicinal chemistry (2024)
Wenhua Jiang, Qiangqiang Hou, Hongrui Xu, Kexin Yang, Xiaohui Wang, Kuojun Zhang, Yi Zeng, Wenqiang Li, Bingrui Wang, Guangmei Luo, Xiaofan Zhao, Hui Shen, Yong Xu, Xiaoxing Wu
Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia. Journal of medicinal chemistry 67 (2) (2024)
Qiu Li, Benqiang Yao, Shiting Zhao, Zhou Lu, Yan Zhang, Qiuping Xiang, Xishan Wu, Haonan Yu, Cheng Zhang, Junhua Li, Xiaoxi Zhuang, Donghai Wu, Yong Li, Yong Xu
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist. Journal of medicinal chemistry 65 (10) (2022)
Jibu Lu, Yongjun Huang, Jing Huang, Rui He, Minhao Huang, Xiaoyun Lu, Yong Xu, Fengtao Zhou, Zhang Zhang, Ke Ding
Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders. Journal of medicinal chemistry 65 (3) (2022)
Tianshi Feng, Xuemei Zhao, Ping Gu, Wah Yang, Cunchuan Wang, Qingyu Guo, Qiaoyun Long, Qing Liu, Ying Cheng, Jin Li, Cynthia Kwan Yui Cheung, Donghai Wu, Xinyu Kong, Yong Xu, Dewei Ye, Shuang Hua, Kerry Loomes, Aimin Xu, Hannah Xiaoyan Hui
Adipocyte-derived lactate is a signalling metabolite that potentiates adipose macrophage inflammation via targeting PHD2. Nature communications 13 (1) (2022)
Qiuping Xiang, Chao Wang, Tianbang Wu, Cheng Zhang, Qingqing Hu, Guolong Luo, Jiankang Hu, Xiaoxi Zhuang, Lingjiao Zou, Hui Shen, Xishan Wu, Yan Zhang, Xiangqian Kong, Jin-Song Liu, Yong Xu
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer. Journal of medicinal chemistry 65 (1) (2021)
Xishan Wu, Hui Shen, Yan Zhang, Chao Wang, Qiu Li, Cheng Zhang, Xiaoxi Zhuang, Chenchang Li, Yudan Shi, Yanli Xing, Qiuping Xiang, Jinxin Xu, Donghai Wu, Jin-Song Liu, Yong Xu
Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist. Journal of medicinal chemistry 64 (12) (2021)
Xishan Wu, Yan Zhang, Yong Xu
Discovery of the First Low Nanomolar Liver Receptor Homolog-1 (LRH-1) Agonist. Journal of medicinal chemistry 62 (24) (2019)
Yan Zhang, Xishan Wu, Xiaoqian Xue, Chenchang Li, Junjian Wang, Rui Wang, Cheng Zhang, Chao Wang, Yudan Shi, Lingjiao Zou, Qiu Li, Zenghong Huang, Xiaojuan Hao, Kerry Loomes, Donghai Wu, Hong-Wu Chen, Jinxin Xu, Yong Xu
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer. Journal of medicinal chemistry 62 (9) (2019)
Qiuju Xun, Zhang Zhang, Jinfeng Luo, Linjiang Tong, Minhao Huang, Zhen Wang, Jian Zou, Yingqiang Liu, Yong Xu, Hua Xie, Zheng-Chao Tu, Xiaoyun Lu, Ke Ding
Design, Synthesis, and Structure-Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5- d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors. Journal of medicinal chemistry 61 (6) (2018)
Maofeng Zhang, Yan Zhang, Ming Song, Xiaoqian Xue, Junjian Wang, Chao Wang, Cheng Zhang, Chenchang Li, Qiuping Xiang, Lingjiao Zou, Xishan Wu, Chun Wu, Baijun Dong, Wei Xue, Yulai Zhou, Hongwu Chen, Donghai Wu, Ke Ding, Yong Xu
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). Journal of medicinal chemistry 61 (7) (2018)
Shulin Hou, Tingting Xu, Jinxin Xu, Linbing Qu, Yong Xu, Ling Chen, Jinsong Liu
Structural basis for functional selectivity and ligand recognition revealed by crystal structures of human secreted phospholipase A2 group IIE. Scientific reports 7 (1) (2017)